
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Associate Director, Marketing, Nordics is the strategic leadership role for the Oncology portfolio, responsible for the integrated management of product launches, brand and omnichannel strategy across the entire Customer Engagement System.
The incumbent ensures that strategic objectives are translated into effective, data-driven and customer-centric initiatives, serving as the connecting leadership function across Product Management, Omnichannel Management, Field Force, Medical Affairs and other Customer-Facing functions.
The Associate Director, Marketing, Nordics will be orchestrating performance, strategic direction, continued development and cross-functional collaboration.
A key element of the role is close and continuous alignment with the European Marketing and Omnichannel organization, ensuring that global and European strategies are consistently translated into locally relevant and market-oriented execution. Furthermore, the consistent alignment and collaboration with Medical Affairs, Strategic Planning and Operations and all other relevant functions is crucial for success.
The Associate Director, Marketing, Nordics does not act as a traditional “planning and approval point”, but as an active enabler of an agile, cross-functional and data-driven Commercial System, with a strong focus on speed, relevance and customer centricity.
This role reports to the Director, Commerc, Nordics.
Primary responsibilities:
Product Launch & Commercial Readiness Leadership
Strategic Portfolio and Marketing Leadership
Omnichannel & Customer Experience Leadership
Integration with Field Force
European Alignment
Innovation, Data & Transformation
Successful candidates combine strategic commercial leadership with strong execution capabilities, digital acumen and a high level of cross-functional influencing ability.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact privacy@revmed.com.
#LI-LO1 #LI-Hybrid
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to careers@revmed.com so we can share these impersonations with our IT team for tracking and awareness.

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.